Digitalis Ventures — 2022 Investments
4 investments dated 2022 · listed companies and verified rows first · show all
Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity.
BiotechHealthtechSeattle, US
John Mulligan(Executive Officer, Director, Promoter)inNeela Patel(Executive Officer)inDiane Hollenbaugh(Executive Officer)in
BoardSamuel Bjork(Director)inMonique Schiersing(Director)inJohn McKearn(Director)in
Co-investorsRiverVest Venture PartnersRoche Venture FundVivo Capital3x5 PartnersCodon Capital
Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
BiotechCambridge, US
Andre Turenne(Executive Officer, Director)in
BoardJason Hafler(Director)inBruce Booth(Director)Daniel Becker(Director)
Co-investorsAccess BiotechnologySanofi VenturesAccess IndustriesAlexandriaAtlas Venture
Centennial, US
Dennis J. Chmiel(Executive Officer, Director)inJen Hagness(Executive Officer, Director)inNancy A. Willerton(Executive Officer, Director)Dennis J. Chmiel Jr.(Executive Officer, Director)
BoardCindy Cole(Director)Jeremy L. Friese(Director)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Napo Pet Insurance
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.













